[Various pharmacological aspects of the treatment of shock].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D009270:Naloxone / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D011459:Prostaglandins E, Synthetic; D009599:Nitroprusside; D009270:Naloxone; D003907:Dexamethasone; D011464:Epoprostenol; D008775:Methylprednisolone
Niektóre farmakologiczne aspekty leczenia wstrzasu.